GRI touts IPF safety edge, lung function gains amid cash crunch
Barreling toward the end of its cash runway, GRI Bio has shared phase 2a data in idiopathic pulmonary fibrosis (IPF) and made the case for further development of its potentially…
Barreling toward the end of its cash runway, GRI Bio has shared phase 2a data in idiopathic pulmonary fibrosis (IPF) and made the case for further development of its potentially…